Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (NASDAQ: RXST) is an ophthalmic medical device company whose news flow centers on its Light Adjustable Lens system and corporate developments related to cataract surgery care. Company press releases describe RxSight as dedicated to providing high-quality customized vision to patients following cataract surgery through its Light Adjustable Lens (LAL/LAL+) and Light Delivery Device (LDD) platform.
News updates for RXST commonly include financial and operating results, such as quarterly revenue, procedure volumes for Light Adjustable Lenses, and the number of Light Delivery Devices sold and installed. These releases often discuss trends in LAL procedure volumes, changes in the installed base of LDDs, and guidance ranges for revenue and gross margin. Investors and observers can use these announcements to track how adoption of the Light Adjustable Lens system is progressing across cataract practices.
RxSight’s news also highlights corporate and leadership developments, including transitions in the Chief Financial Officer role and appointments to the Board of Directors and Board committees, as disclosed in press releases and related Form 8-K filings. In addition, the company regularly announces participation in major healthcare and ophthalmology conferences, where management presents to investors and engages with surgeons and other stakeholders.
Another recurring theme in RxSight’s news is commercial and clinical engagement activity. The company has reported initiatives such as practice development programs and Live Learning Sessions at ophthalmology meetings, where surgeons share real-world experience with the Light Adjustable Lens and discuss clinical and practice-level impacts.
This RXST news page aggregates these types of updates in one place, allowing readers to follow RxSight’s reported financial performance, leadership changes, conference participation, and initiatives related to its Light Adjustable Lens technology over time.
RxSight (NASDAQ:RXST) will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026 at 3:00 p.m. PT. Management will take part in a fireside chat. A live and archived webcast will be available on the company’s investor relations website.
RxSight (NASDAQ: RXST) will report first-quarter 2026 financial results on May 6, 2026 after market close.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with dial-in numbers and a listen-only webcast on the company investor relations site; an archived recording will be posted after the call.
RxSight (NASDAQ: RXST) announced it has surpassed 300,000 Light Adjustable Lens (LAL) implants since launch and will feature 35 scientific presentations at ASCRS 2026.
Company highlights include published outcomes showing high refractive accuracy and a new surgeon-focused outreach program to expand patient access.
RxSight (NASDAQ: RXST) will present at the 25th Annual Needham Virtual Healthcare Conference. Management will participate in a fireside chat on April 16, 2026 at 8:00 a.m. PT. A live and archived webcast will be available on the company investor relations website.
RxSight (NASDAQ: RXST) reported 2025 results: full-year revenue of $134.5 million (down 4%), gross profit of $103.0 million (76.6% margin), and a net loss of $38.9 million (‑$0.95 per share).
LAL unit sales rose 12% to 109,615 units; LDD system sales fell 48% with 163 units. Cash and short-term investments totaled $228.1 million. 2026 guidance: revenue $120.0–$135.0 million, gross margin 70%–72%, operating expenses $150.0–$160.0 million.
RxSight (NASDAQ:RXST) will report fourth quarter and full year 2025 financial results after market close on February 25, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and take questions.
Dial-in numbers, conference code 3406720, a live listen-only webcast and an archived recording will be available on the company’s investor relations website.
RxSight (Nasdaq: RXST) reported preliminary unaudited results for Q4 and full-year 2025 and named a new CFO effective Jan 11, 2026. Preliminary Q4 2025 revenue is expected to be approximately $32.6M, driven by sales of 28,611 Light Adjustable Lenses (LAL, +10% vs Q3 2025) and 25 Light Delivery Devices (LDD), bringing the installed base to 1,134 LDDs as of Dec 31, 2025. Preliminary FY2025 revenue is expected to be approximately $134.5M (vs prior guidance $125–$130M), with total LAL sales of 109,615 (+12% vs 2024) and 163 LDDs sold in 2025. Cash and short-term investments are expected to be $228.1M. Audited 2025 results and 2026 guidance will be released with Q4 earnings in February. Mark Wilterding is appointed CFO effective Jan 11, 2026.
RxSight (NASDAQ:RXST) announced that its management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 3:45 p.m. PT / 6:45 p.m. ET.
Investors and interested parties can access a live and archived webcast of the presentation at https://investors.rxsight.com/. No financial results or guidance were included in the announcement.
RxSight (NASDAQ:RXST) announced that Shelley Thunen, its Chief Financial Officer, is transitioning from the CFO role and will remain with the company until the sooner of her successor's appointment or January 31, 2026. Ms. Thunen has agreed to support RxSight as a consultant after the transition.
The release highlights Ms. Thunen's nearly decade of service, her role in the company's 2021 IPO, and operational achievements under her finance leadership, including more than 1,100 light-adjustable intraocular devices (LDDs) in the field and over 250,000 procedures performed. The CEO and board expressed gratitude for her contributions.
RxSight (NASDAQ: RXST) will present at the Piper Sandler 37th Annual Healthcare Conference in New York City.
Management is scheduled to present on Wednesday, December 3, 2025 at 12:00 p.m. ET. A live and archived webcast will be available at the company's investor site.